These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6235402)

  • 1. The immunomodulating effect of TP5 and indomethacin in burn-induced hypoimmunity.
    Maghsudi M; Miller CL
    J Surg Res; 1984 Aug; 37(2):133-8. PubMed ID: 6235402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Studies of thymopoietin pentapeptide (TP5) on experimental tumors. I. TP5 relieves immunosuppression in tumor-bearing mice.
    Lau CY; Wang EY; Goldstein G
    Cell Immunol; 1982 Jan; 66(2):217-32. PubMed ID: 6802504
    [No Abstract]   [Full Text] [Related]  

  • 3. Thymopentin (TP-5) in the treatment of the postburn and postoperative immunodeficiency syndrome.
    Hamilton G; Zöch G; Rath T; Meissl G
    Prog Clin Biol Res; 1989; 308():995-9. PubMed ID: 2528748
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of synthetic thymic hormone (TP5) in children with T-cell immunodeficiencies.
    Levinsky RJ; Davies EG; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):273-6. PubMed ID: 6360239
    [No Abstract]   [Full Text] [Related]  

  • 5. Abrogation of in vitro suppressor cell activity in adult common variable hypogammaglobulinemia after TP5 treatment.
    Williams RC; Montano JD; Bankhurst AD
    J Lab Clin Med; 1983 Jan; 101(1):152-60. PubMed ID: 6217268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of the CD4/CD8 lymphocyte ratio and increased B lymphocytes in long standing diabetic patients following therapy with thymopentin.
    Pozzilli P; Visalli N; Cavallo MG; Beales P; Negri M; Ghirlanda G; Papa V; Andreani D
    Diabetes Res; 1987 Oct; 6(2):51-6. PubMed ID: 2962799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stimulation of cellular function by thymopentin (TP-5) in three AIDS patients.
    Mascart-Lemone F; Huygen K; Clumeck N; Brenez D; Bolla K; Duchateau J
    Lancet; 1983 Sep; 2(8352):735-6. PubMed ID: 6193382
    [No Abstract]   [Full Text] [Related]  

  • 8. An immunomodulating drug, thymopentin, in the treatment of progressive systemic sclerosis.
    Giordano N; Biasi G; Taddeo A; Marcolongo R; Bertelletti D
    Clin Rheumatol; 1989 Jun; 8(2):293-4. PubMed ID: 2667863
    [No Abstract]   [Full Text] [Related]  

  • 9. [Model for acquired immunodeficiency caused by anesthesia and surgical procedures. Effect of treatment with thymopoietin pentapeptide (TP5)].
    Auteri A; D'Aniello C; Falotico N; Saletti M; Di Perri T
    Recenti Prog Med; 1986 Sep; 77(9):423-8. PubMed ID: 3541085
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of marrow graft recipients with thymopentin.
    Witherspoon RP; Navari R; Storb R; Sullivan KM; Doney K; Beatty P; Lum LG; Thomas ED
    Bone Marrow Transplant; 1987 Apr; 1(4):365-71. PubMed ID: 3332144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with thymopoietin pentapeptide (TP-5) in 26 patients with primary immunodeficiencies.
    Aiuti F; Businco L; Fiorilli M; Galli E; Quinti I; Le Moli S; Seminara R; Goldstein G
    Birth Defects Orig Artic Ser; 1983; 19(3):267-72. PubMed ID: 6360238
    [No Abstract]   [Full Text] [Related]  

  • 12. Thymopentin in experimental and clinical medicine.
    Surv Immunol Res; 1985; 4 Suppl 1():1-156. PubMed ID: 3898279
    [No Abstract]   [Full Text] [Related]  

  • 13. Rationale for thymopentin as therapeutic agent in rheumatoid arthritis.
    Franchimont P; Bolla K
    Surv Immunol Res; 1985; 4 Suppl 1():70-5. PubMed ID: 3898295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thymopentin and immune response in patients with cancer].
    Petronella P; Ferrone R; Freda F; Valeriani G
    Minerva Chir; 1989 Sep; 44(18):2017-20. PubMed ID: 2694011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of action of two new immunomodulators.
    Waymack JP; Gonce S; Miskell P; Alexander JW
    Arch Surg; 1985 Jan; 120(1):43-8. PubMed ID: 3917663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic use of TP5 (thymopoietin 32-36) in sarcoidosis of the skin.
    Thivolet J; Faure M; Nicolas JF; Mauduit G; Claudy A
    Clin Immunol Immunopathol; 1983 Mar; 26(3):350-60. PubMed ID: 6347481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A prospective study of thymopentin in severely burned patients.
    Waymack JP; Jenkins M; Warden GD; Solomkin J; Law E; Hummel R; Miller A; Alexander JW
    Surg Gynecol Obstet; 1987 May; 164(5):423-30. PubMed ID: 3554564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of thymopentin on the anaemia of myelodysplastic syndromes. A preliminary study.
    Catarini M; Sebastianelli G; Romagnoli R; Leoni P
    Recenti Prog Med; 1989 Jan; 80(1):46. PubMed ID: 2652223
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of thymopentin on the anaemia of chronic lymphoproliferative disorders.
    Paladini G; Tosato F
    Haematologica; 1986; 71(6):519-20. PubMed ID: 3104165
    [No Abstract]   [Full Text] [Related]  

  • 20. Thymopentin in the treatment of alopecia areata.
    Orecchia G
    Dermatologica; 1989; 178(4):231. PubMed ID: 2670621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.